Apraclonidine

Apraclonidine

SCHEMBL34128

Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2C

The experimentally established mechanism targets of Apraclonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A known ✓ P08913 9/20 1.00
ADRA2B known ✓ P18089 8/20 1.00
ADRA2C known ✓ P18825 8/20 1.00
ADRA1A P35348 4/20 1.00
ADRA1D P25100 3/20 1.00
ADRA1B P35368 3/20 1.00
TSHR P16473 2/20 1.00
NFKB1 P19838 2/20 1.00
HSD17B10 Q99714 1/20 1.00
BLM P54132 3/20 0.97
HTR1D P28221 4/20 0.71
CYP2D6 P10635 3/20 0.71
NISCH Q9Y2I1 3/20 0.71
HTR1B P28222 3/20 0.71
CYP1A2 P05177 1/20 0.71
LMNA P02545 5/20 0.69
HIF1A Q16665 2/20 0.66
HRH2 P25021 2/20 0.66
MEN1 O00255 1/20 0.66
SLC22A1 O15245 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Apraclonidine SCHEMBL1649431 0.98 ADRA2A (0.97) ADRA2AADRA2BADRA2CADRA1AADRA1D
Apraclonidine SCHEMBL1002875 0.98 BLM (1.00) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL11180812 0.86 ADRA2A (0.76) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL11761437 0.83 ADRA2C (0.71) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL10414088 0.83 ADRA2A (0.71) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL24658874 0.83 ADRA2A (0.71) ADRA2AADRA2BADRA2CADRA1AADRA1D
Pi-Clonidine SCHEMBL563884 0.83 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1AADRA1D
Bromide SCHEMBL11608848 0.82 ADRA2A (0.69) ADRA2AADRA2BADRA2CADRA1AADRA1D
Pi-Clonidine SCHEMBL5274141 0.82 LMNA (1.00) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL27281113 0.80 ADRA2A (0.67) ADRA2AADRA2BADRA2CADRA1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7895 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144679-A1 Vasoconstriction for eye treatments BELKIN VISION LTD. (IL) 2026-05-28 US claimed
EP-4739302-A2 HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS Cella Therapeutics, LLC (US) 2026-05-13 EP claimed
EP-4724079-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Stealth BioTherapeutics Inc. (US) 2026-04-15 EP claimed
EP-4724839-A2 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS Mediprint Ophthalmics Inc. (US) 2026-04-15 EP claimed
US-20260090984-A1 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS MEDIPRINT OPHTHALMICS INC. (US) 2026-04-02 US claimed
EP-4710918-A1 OPHTHALMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR, OPHTHALMIC KIT CONTAINING OPHTHALMIC PHARMACEUTICAL COMPOSITION, AND USE Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) 2026-03-18 EP claimed
US-12577562-B2 Treatment of glaucoma with Rho Guanine Nucleotide Exchange factor 12 (ARHGEF12) inhibitors REGENERON PHARMACEUTICALS, INC. (US) 2026-03-17 US claimed
EP-4704839-A2 IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF ALPHERABIO LLC (US) 2026-03-11 EP claimed
US-20260048096-A1 METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS STEALTH BIOTHERAPEUTICS INC. (US) 2026-02-19 US claimed
EP-4683616-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING APRACLONIDINE FOR OCULAR REDNESS RELIEF Alcon Inc. (CH) 2026-01-28 EP claimed
EP-0550921-A1 Pharmaceutical composition for ophthalmic use comprising a nonsteroidal anti-inflammatory and a decongestant drug ZAMBON GROUP S.p.A. (IT) 1993-07-14 EP claimed
US-5215991-A Administering amiloride and an imidazolidine derivative ALLERGAN, INC. (US) 1993-06-01 US claimed
US-5180721-A Imidazoline substituted naphthalene compounds for treatment of glaucoma ALLERGAN, INC. (US) 1993-01-19 US claimed
WO-1992021349-A1 COMBINATIONS OF ALPHA-2 ADRENERGIC AGONISTS WITH ALPHA-3 ANTAGONISTS FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN, INC. (US) 1992-12-10 WO claimed
EP-0507224-A2 Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions ALCON LABORATORIES, INC. (US) 1992-10-07 EP claimed
EP-0170193-B1 FEEDSTUFF ADDITIVE FOR THE GROWTH PROMOTING OF AGRICULTURAL USEFUL ANIMALS BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 1991-12-27 EP claimed
EP-0429732-A1 Sustained-release compositions containing cation exchange resins and polycarboxylic polymers ALCON LABORATORIES, INC. (US) 1991-06-05 EP claimed
EP-0399791-A1 Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure ALLERGAN, INC (US) 1990-11-28 EP claimed
US-4853402-A 2-SUBSTITUTED-2-IMIDAZOLINES BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 1989-08-01 US claimed
EP-0170193-A2 Feedstuff additive for the growth promoting of agricultural useful animals BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 1986-02-05 EP claimed